Clinicopathologic significance of TROP2 and phospho‑TROP2 in gastric cancer

Kushiyama,Shuhei; Yashiro,Masakazu; Yamamoto,Yurie; Sera,Tomohiro; Sugimoto,Atsushi; Nishimura,Sadaaki; Togano,Shingo; Kuroda,Kenji; Yoshii,Mami; Tamura,Tatsuro; Toyokawa,Takahiro; Tanaka,Hiroaki; Muguruma,Kazuya; Nakada,Hiroshi; Ohira,Masaichi

doi:10.3892/mco.2021.2267

Clinicopathologic significance of TROP2 and phospho‑TROP2 in gastric cancer

Authors:
- Shuhei Kushiyama
- Masakazu Yashiro
- Yurie Yamamoto
- Tomohiro Sera
- Atsushi Sugimoto
- Sadaaki Nishimura
- Shingo Togano
- Kenji Kuroda
- Mami Yoshii
- Tatsuro Tamura
- Takahiro Toyokawa
- Hiroaki Tanaka
- Kazuya Muguruma
- Hiroshi Nakada
- Masaichi Ohira
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan, Department of Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan, Department of Molecular Biosciences, Faculty of Life Science, Kyoto Sangyo University, Kyoto 603‑8555, Japan
Published online on: March 19, 2021 https://doi.org/10.3892/mco.2021.2267
Article Number: 105
Copyright: © Kushiyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Trophoblast cell‑surface antigen 2 (TROP2) is a transmembrane glycoprotein expressed in epithelial cells. Increased TROP2 expression has been reported to be associated with malignant progression in most carcinomas; however, TROP2 has a tumor‑suppressive function in certain types of cancer. Since the function of TROP2 is controversial, the present study subsequently aimed to clarify the clinicopathologic significance of TROP2 and pTROP2 expression in human gastric cancer (GC). The cases of 704 patients with GC who underwent gastrectomy were retrospectively analyzed. The expression levels of TROP2 and pTROP2 in each tumor were evaluated by immunohistochemistry. The association between the clinicopathologic features of patients with GC and the levels of TROP2 and pTROP2 in their tumors was analyzed. Increased TROP2 and pTROP2 expression was identified in 330 (46.9%) and 306 (43.5%) of the 704 patients with GC, respectively. Increased TROP2 expression was associated with the histological intestinal type, high tumor invasion depth (T3/T4), lymph node metastasis, lymphatic invasion and venous invasion. By contrast, increased pTROP2 expression was associated with intestinal type, low tumor invasion depth (T1/2), no lymph node metastasis and no lymphatic invasion. Increased TROP2 expression was associated with poorer overall survival (OS) (P<0.01; log rank test), whereas increased pTROP2 expression was significantly associated with improved OS (P<0.01; log rank test). In conclusion, increased expression levels of TROP2, but not pTROP2, may be associated with the metastatic ability of GC, resulting in poor prognosis of patients with GC.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–548. 2017.PubMed/NCBI View Article : Google Scholar
2	Fornaro L, Vasile E, Aprile G, Goetze TO, Vivaldi C, Falcone A and Al-Batran SE: Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treat Rev. 69:90–100. 2018.PubMed/NCBI View Article : Google Scholar
3	Gambardella V and Cervantes A: Precision medicine in the adjuvant treatment of gastric cancer. Lancet Oncol. 19:583–584. 2018.PubMed/NCBI View Article : Google Scholar
4	Wanger TM, Dewitt S, Collins A, Maitland NJ, Poghosyan Z and Knauper V: Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17. Cell Signal. 27:1325–1335. 2015.PubMed/NCBI View Article : Google Scholar
5	Cubas R, Li M, Chen C and Yao Q: Trop2: A possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 1796:309–314. 2009.PubMed/NCBI View Article : Google Scholar
6	Vidmar T, Pavsic M and Lenarcic B: Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain. Protein Expr Purif. 91:69–76. 2013.PubMed/NCBI View Article : Google Scholar
7	Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S and Geradts J: Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res. 11:4357–4364. 2005.PubMed/NCBI View Article : Google Scholar
8	Shvartsur A and Bonavida B: Trop2 and its overexpression in cancers: Regulation and clinical/therapeutic implications. Genes Cancer. 6:84–105. 2015.PubMed/NCBI View Article : Google Scholar
9	Guerra E, Trerotola M, Dell' Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C, Lorenzini F, Rossi C, et al: A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res. 68:8113–8121. 2008.PubMed/NCBI View Article : Google Scholar
10	Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, Jou YS, Hong TM and Yang PC: TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 4:472–485. 2012.PubMed/NCBI View Article : Google Scholar
11	Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, Wang B, Wen J, Qiu Z, Ding G, et al: Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. 7:6136–6145. 2016.PubMed/NCBI View Article : Google Scholar
12	Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Zitt M, Müller HM, Margreiter R, et al: TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 62:152–158. 2009.PubMed/NCBI View Article : Google Scholar
13	Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G and Spizzo G: High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 99:1290–1295. 2008.PubMed/NCBI View Article : Google Scholar
14	Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M and Laimer K: TROP2: A novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 21:186–191. 2008.PubMed/NCBI View Article : Google Scholar
15	Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF and Wan DS: Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 24:875–884. 2009.PubMed/NCBI View Article : Google Scholar
16	Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, et al: Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 46:944–953. 2010.PubMed/NCBI View Article : Google Scholar
17	Sin STK, Li Y, Liu M, Ma S and Guan XY: TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling. Gynecol Oncol. 152:185–193. 2019.PubMed/NCBI View Article : Google Scholar
18	Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, et al: Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget. 5:9281–9294. 2014.PubMed/NCBI View Article : Google Scholar
19	Mori Y, Akita K, Ojima K, Iwamoto S, Yamashita T, Morii E and Nakada H: Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C α/δ (PKC α/δ) enhances cell motility. J Biol Chem. 294:11513–11524. 2019.PubMed/NCBI View Article : Google Scholar
20	Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J and Witte ON: Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. Genes Dev. 26:2271–2285. 2012.PubMed/NCBI View Article : Google Scholar
21	Soini Y, Tommola S, Helin H and Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch. 448:52–58. 2006.PubMed/NCBI View Article : Google Scholar
22	Stanculescu D, Margaritescu C, Stepan A and Mitrut AO: E-cadherin in gastric carcinomas related to histological prognostic parameters. Rom J Morphol Embryol. 52 (Suppl 3):S1107–S1112. 2011.PubMed/NCBI
23	Larsson O, Girnita A and Girnita L: Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 92:2097–2101. 2005.PubMed/NCBI
24	Rosenzweig SA and Atreya HS: Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 80:1115–1124. 2010.PubMed/NCBI View Article : Google Scholar
25	Chiarle R, Voena C, Ambrogio C, Piva R and Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 8:11–23. 2008.PubMed/NCBI View Article : Google Scholar
26	Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, et al: Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 380:741–751. 2019.PubMed/NCBI View Article : Google Scholar